Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ark Biosciences In-Licenses Pulmonary Fibrosis Candidate from Roche

publication date: Sep 3, 2018

Ark Biosciences, a Shanghai-Suzhou clinical stage biotech, has in-licensed global rights to a treatment for idiopathic pulmonary fibrosis (IPF) from Roche. Ark believes the candidate, which has completed its first-in--human trial, has the potential to become standard-of-care. Ark will be responsible for milestone and royalty payments, and Roche will retain certain preferential rights, though further details were not disclosed. Ark has its own innovative drug R&D operations for respiratory and infectious disease, while also in-licensing promising candidates. More details....

Stock Symbol: (SWX: ROG)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here